Myhep All Tablet

Myhep All Tablet

Prescription requiredRx Required

Salt Composition: Sofosbuvir and Velpatasvir

Expiry Date: 01/2028

Special offer

Buy at $98.00

$98.00

Inclusive of all taxes

28 tablet

About The Product

Chronic hepatitis C virus (HCV) infection

  • Two antiviral medications are combined in Myhep All Tablet.
  • Chronic hepatitis C virus (HCV) infection is treated with this prescription medication.
  • The active ingredients of Myhep All tablets are Velpatasvir and Sofosbuvir.
  • It helps by reducing the virus's ability to multiply within the body. .
  • The duration of time may vary depending on a number of factors, including liver cirrhosis, prior treatment history, and HCV genotype.
  • Reducing the virus may significantly decrease the incidence of liver cirrhosis, liver failure, and hepatocellular carcinoma, a kind of liver cancer.


Uses

Chronic hepatitis C (HCV) infection.

Side Effects

Myhep All tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional. If you've had hepatitis B in the past, taking Myhep All Tablet can make the virus active again. Before you start treatment your doctor will test you for hepatitis B and, if necessary, monitor you closely. Some common side effects are:

  • Anemia
  • Headache
  • Fatigue
  • Nausea
  • Insomnia
  • Diarrhea
  • Itching
  • Decreased appetite
  • Muscle or joint pain
  • Dizziness

Dosage and Administration

  • Take this medicine exactly as directed by your doctor, in the prescribed dose and for the recommended duration.
  • Swallow the whole tablet, do not chew, crush, or break it.
  • Myhep All Tablet can be taken with or without food, but it is best to take it at the same time each day.

Mechanism of action

  • Sofosbuvir and Velpatasvir are two antiviral medications that are combined in Myhep All Tablet.
  • They function by gradually removing the hepatitis C virus from the blood and reducing its levels in the body.
  • By focusing on a particular protein required for viral reproduction, the direct-acting antiviral medication (DAA) sofosbuvir prevents the HCV virus from replicating.
  • Another DAA that functions by preventing the activity of a different protein implicated in HCV replication is velpatasvir.

Safety Advice

Alcohol

It is unclear whether consuming alcohol with Myhep All Tablet is safe. It is generally advised to avoid drinking alcohol during hepatitis C treatment while taking the Myhep All Tablet. Alcohol may worsen liver damage and reduce the effectiveness of the medication. For guidance on alcohol use during treatment, consult your healthcare provider.

Pregnancy

Do not take ​Myhep All tablet without consulting the doctor in case of pregnancy because there is limited information available regarding the safety of using Myhep All Tablet during pregnancy.

Breast Feeding

Without a doctor's consultation, do not take this medicine if you're breastfeeding.

Driving

It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.

Kidney

Do not take ​Myhep 400 mg tablet without a doctor's consultation in case of kidney problems.

Liver

Share your medical history with the doctor in case of liver disease before taking this medicine.

Missed Doses

  • If you miss a dose of Myhep All Tablet, take it as soon as you remember.
  • If it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing routine.
  • Do not take a double dose to make up for the missed one.

FAQs

Myhep All Tablet medicine is a combination of Sofosbuvir and Velpatasvir, which are also called antiviral medicines.

It is used for Chronic hepatitis C virus (HCV) infection.

References

  • Butt, N., Muhammad, I., Abou Bakr, A., Akhtar, Z., Ali, M., & Maheshwary, N. (2020). Efficacy and safety of Sofosbuvir-velpatasvir combination in Pakistani HCV patients without or with compensated cirrhosis. Cureus, 12(1), e6537. https://doi.org/10.7759/cureus.6537
  • Goel, A., Chen, Q., Chhatwal, J., & Aggarwal, R. (2018). Cost-effectiveness of generic pan‑genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment in India. Journal of Gastroenterology and Hepatology, 33(12), 2029–2036. https://doi.org/10.1111/jgh.14301
  • Tan, Y. M., et al. (2023). Real‑world impact of the subsidy decision of sofosbuvir‑velpatasvir for chronic hepatitis C: trends in utilization and SVR outcomes in Malaysia. JGH Open. https://doi.org/10.1002/jgh3.12850
  • Springer. Gaur, N., et al. (2020). Sofosbuvir‑velpatasvir fixed-dose combination for chronic hepatitis C infection in end-stage renal disease patients on maintenance hemodialysis: An Indian single-center experience. Journal of Clinical and Experimental Hepatology. Retrieved from PubMed. Shah, V., et al. (2023). Sofosbuvir/velpatasvir/voxilaprevir for retreatment of difficult-to-treat chronic HCV patients in India: Real-life observational cohort. Journal of Clinical and Experimental Hepatology. https://pubmed.ncbi.nlm.nih.gov/38261859/
  • Huang, C.-T., et al. (2021). Sofosbuvir/velpatasvir for chronic hepatitis C virus infection: real‑world effectiveness and safety from a nationwide registry in Taiwan. Infectious Diseases and Therapy, 10(3), 1185–1196. https://doi.org/10.1007/s40121-021-00576-7

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026